Cagrilintide / Semaglutide

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

Cagrilintide / Semaglutide Blend — Amylin / GLP-1R Dual-Pathway Research Stack (CagriSema)

The Cagrilintide / Semaglutide blend — studied clinically under the designation CagriSema — pairs two long-acting, once-weekly peptides operating through entirely distinct receptor systems into a single research compound. Semaglutide engages the GLP-1 receptor in the hypothalamus and other central appetite circuits, driving appetite suppression, insulin secretion, and glucagon inhibition through the incretin pathway. Cagrilintide engages amylin receptors (AMY1R, AMY3R) and the calcitonin receptor (CTR) primarily in the caudal hindbrain — the area postrema and nucleus tractus solitarius — driving meal-ending satiation and gastric emptying delay through a neuroanatomically distinct pathway. The combination activates both the homeostatic and hedonic satiety circuits of the brain simultaneously, producing outcomes that demonstrably exceed either compound alone.

This is the most clinically advanced amylin/GLP-1 dual-pathway combination in the metabolic research literature. REDEFINE phase 3 trial data published in the New England Journal of Medicine (June 2025) make it one of the best-characterized research peptide combinations available — providing an unusually robust preclinical-to-clinical data bridge for researchers studying dual-circuit satiety, energy balance, and cardiometabolic endpoints.

Why the GLP-1R + Amylin/CTR Combination Matters

The core insight driving CagriSema research is that GLP-1 and amylin signaling access appetite regulation through different neuroanatomical entry points. GLP-1R agonism operates predominantly through the hypothalamic arcuate nucleus and related forebrain structures. Amylin receptor agonism operates predominantly through the caudal hindbrain — a region critical for meal-ending satiation that GLP-1R agonism does not fully engage. Activating both circuits simultaneously produces an additive and, in some endpoints, synergistic suppression of food intake that neither pathway can achieve in isolation.

The REDEFINE 1 trial provides direct head-to-head comparator data: mean body weight reduction of -20.4% (CagriSema) vs. -14.9% (semaglutide alone) vs. -11.5% (cagrilintide alone) vs. -3.0% (placebo) at 68 weeks — making the combination’s additive contribution precisely quantifiable in research models.

Research Applications

The Cagrilintide / Semaglutide blend is used in studies examining:

• Dual-circuit satiety biology — the additive and synergistic interaction between hypothalamic GLP-1R signaling and hindbrain amylin receptor signaling
• Dose-response characterization of the combination vs. matched monotherapy controls, using the REDEFINE trial design as a reference framework
• Body composition endpoints including lean mass preservation alongside fat mass reduction under dual-pathway appetite suppression
• Cardiometabolic parameters including blood pressure, waist circumference, lipid profiles, and glycemic control under sustained co-administration
• Glucose homeostasis in metabolic models, including prediabetes reversal and HbA1c reduction in T2D-adjacent research
• Mechanisms underlying weight loss outcomes that exceed the additive predictions of monotherapy data — investigating receptor crosstalk, neural circuit co-modulation, and downstream hormonal signaling
• Comparative positioning relative to GLP-1 mono-agonists (semaglutide), dual incretin agonists (tirzepatide), and triple agonists (retatrutide) across matched metabolic endpoints
• Long-duration weight maintenance protocols and resistance to weight regain following initial loss

Specifications

Reconstitution

The blend arrives as co-lyophilized powder and is reconstituted as a single solution with bacteriostatic water prior to use. Use the formula:

Total mg (per peptide) ÷ Volume added (mL) = Concentration per peptide (mg/mL)

Example: 5mg/5mg vial + 2mL BAC water = 2.5mg/mL Cagrilintide + 2.5mg/mL Semaglutide

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

Both peptides in this blend share a long half-life profile compatible with once-weekly dosing. The REDEFINE clinical trial program — the most detailed published protocol for this combination — employed a parallel titration schedule starting both peptides at 0.25mg and escalating simultaneously every 4 weeks, allowing GI adaptation to the compounded receptor engagement of both pathways before reaching target doses.

Typical titration framework:

• Starting dose: 0.25mg per peptide per administration
• Escalation: Increase both peptides by 0.25–0.5mg every 2–4 weeks as tolerated
• Frequency: Once weekly (consistent with the long half-life profile of both peptides)
• Titration note: Combined GI effects of dual-pathway activation are most pronounced during escalation; the two pathways compound nausea risk via independent mechanisms
• Study duration: 12–20 weeks for body composition endpoints; 68-week protocols used in REDEFINE for comprehensive cardiometabolic characterization

Commonly observed effects in research models:

• GI-related (receptor-mediated, dual-pathway, typically transient): Nausea, vomiting, diarrhea, constipation, abdominal pain — reported in 79.6% of REDEFINE 1 combination participants vs. 39.9% placebo; predominantly mild-to-moderate and resolving with continued dosing. GI burden is higher than either monotherapy alone given independent receptor contributions from both pathways
• Metabolic: Significant reductions in food intake and body weight; postprandial glucagon suppression via both GLP-1R and amylin receptor pathways; fluid balance and electrolyte shifts at sustained higher doses
• Other: Injection site reactions; headache; fatigue; mild dizziness — profile broadly consistent with GLP-1R agonist class plus additive amylin receptor effects

Research Stacks

Cagrilintide / Semaglutide is commonly paired in research settings with:

• Tirzepatide — Tirzepatide’s GIP receptor activity adds a third incretin axis to the amylin + GLP-1 coverage of this blend; researchers study the combination to characterize additive signaling in hypothalamic energy regulation models.
• CJC-1295 No DAC / Ipamorelin — The GHRH/ghrelin receptor pairing is studied alongside Cagrilintide/Semaglutide in multi-axis metabolic models where GH secretion and incretin/amylin signaling are examined concurrently.
• MOTS-c — MOTS-c activates AMPK through a nuclear-encoded mitochondrial pathway; it is paired with this blend to examine downstream metabolic effects at the cellular level in conjunction with receptor-mediated appetite and energy signaling.

Purity Guarantee

Every batch is ≥99% purity per peptide. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.